FHI Clinical Inc. Expands Support in PREVAIL Research Network
FHI Clinical Inc. has announced that it has expanded its support role in the PREVAIL clinical research network, or Partnership for Research on Vaccines and Infectious Diseases in Liberia, to include full operational management. The goal is to sustain the ability of the network’s research-ready sites to conduct research in collaboration with sponsors and research teams, with a focus on emergent and high-impact public health research priorities in Liberia.
FHI Clinical oversees and facilitates the execution and contractual requirements of in-country logistics. These tasks include sourcing, procuring and shipping; all staff hiring; staff training, including good clinical practice, laboratory practices, data management, computer skills, record keeping, etc.; facility management; and renovation project management.
The research network was originally established in 2014 by the Liberian Ministry of Health and U.S. Department of Health and Human Services in response to the 2014-2015 Ebola outbreak.
To read the full release, click here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
